Status:
COMPLETED
Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients
Lead Sponsor:
University of Oslo School of Pharmacy
Conditions:
Renal Transplant Recipients
Posttransplant Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primar...
Eligibility Criteria
Inclusion
- Reduced glucose tolerance (fasting glucose \< 6.1 mmol/L AND 2 hour glucose between 6.7 and 9.9 mmol/L) or posttransplant diabetes mellitus (fasting glucose \> 6.1 mmol/L OR 2 hour glucose between \>= 10.0 mmol/L)
- Stable patients fgollowing renal transplantation, less than 25% variation in serum creatinine last week and serum creatinine \< 200 micromol/L
Exclusion
- Patients with indulin dependent diabetes mellitus before or after transplantation
- Planned change in daily prednisolone dose during the study period
- Haemoglobin \< 8g/dL
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
November 1 2003
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00319189
Start Date
November 1 2002
End Date
November 1 2003
Last Update
May 10 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rikshospitalet, Section of Nephrology
Oslo, Norway, 0027